Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
DiagnostykaFRA:7JS +0.26%26 3-Year FCF Growth Rate is 21.30% as of Mar. 2026. GuruFocus rates FRA:7JS with a GF Score™ of 26/100. The stock has 1 warning sign investors should review. Among 152 Medical Diagnostics & Research companies, Diagnostyka ranks better than 57.89% on this metric.
During the past 12 months, Diagnostyka's average Free Cash Flow per Share Growth Rate was 13.00% per year.
During the past 3 years, the average Free Cash Flow per Share Growth Rate was 21.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.
During the past 5 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Diagnostyka was 21.30% per year. The lowest was -22.50% per year. And the median was -0.60% per year.
Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.
Diagnostyka 3-Year FCF Growth Rate Related Terms
FRA:7JS vs TMO, DHR, NTRA: 3-Year FCF Growth Rate Comparison
For the Diagnostics & Research subindustry, Diagnostyka's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Diagnostyka 3-Year FCF Growth Rate vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Diagnostyka's 3-Year FCF Growth Rate distribution charts can be found below:
* The bar in red indicates where Diagnostyka's 3-Year FCF Growth Rate falls into.
This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.
What does a 3-Year FCF Growth Rate of 21.30% mean?
Diagnostyka (FRA:7JS) has a 3-Year FCF Growth Rate of 21.30% as of Mar. 2026. 3-Year FCF Growth Rate is the 3-year average growth rate of Free Cash Flow per Share. View historical data for Diagnostyka and its competitors. According to the industry distribution chart, Diagnostyka ranks #64 out of 152 companies in the Medical Diagnostics & Research industry, placing it in the top 42.1%.
Is Diagnostyka's 3-Year FCF Growth Rate too high?
Diagnostyka's current 3-Year FCF Growth Rate is 21.30%. The Medical Diagnostics & Research industry median 3-Year FCF Growth Rate is 16.05. Diagnostyka's value of 21.30% is 32.7% above this industry median. Based on the distribution chart, Diagnostyka ranks #64 out of 152 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Diagnostyka has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Diagnostyka's 3-Year FCF Growth Rate compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Diagnostyka ranks #64 out of 152 companies for 3-Year FCF Growth Rate. This puts Diagnostyka in the upper half of its industry. The industry median 3-Year FCF Growth Rate is 16.05. Diagnostyka's value of 21.30% is 32.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year FCF Growth Rate for a Medical Diagnostics & Research company?
The median 3-Year FCF Growth Rate among Medical Diagnostics & Research companies is 16.05, based on 152 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year FCF Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year FCF Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Diagnostyka's current 3-Year FCF Growth Rate of 21.30% is 32.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year FCF Growth Rate mean?
A high 3-Year FCF Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year FCF Growth Rate is the 3-year average growth rate of Free Cash Flow per Share. View historical data for Diagnostyka and its competitors. For the Medical Diagnostics & Research industry, the median 3-Year FCF Growth Rate is 16.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Diagnostyka's current 3-Year FCF Growth Rate is 21.30%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diagnostyka stock overvalued right now?
Diagnostyka (FRA:7JS) has a current 3-Year FCF Growth Rate of 21.30%. The current 3-Year FCF Growth Rate is 21.30% and 32.7% above the Medical Diagnostics & Research industry median of 16.05. Diagnostyka's overall GF Score™ is 26/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year FCF Growth Rate calculated?
3-Year FCF Growth Rate is calculated from a company's financial statements. For Diagnostyka (FRA:7JS), the current 3-Year FCF Growth Rate is 21.30% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Diagnostyka SA is engaged in providing laboratory diagnostics services in Poland. The company offers comprehensive laboratory services from collecting biological material, through testing, to providing results online.
26GF Score
Get the complete analysis for FRA:7JS
3-Year FCF Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:7JS has been successfully added to your 
